Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934738 | 0.85 | ALDH1A1 (0.37) | GAAALDH1A1PDE10ASMN1; SMN2LMNA | |
| SCHEMBL20428062 | 0.85 | ALDH1A1 (0.34) | GAAALDH1A1PDE10ASMN1; SMN2LMNA | |
| SCHEMBL21771191 | 0.82 | PDE10A (0.36) | ALDH1A1PDE10ADRD1RAB9A | |
| SCHEMBL3820870 | 0.82 | ALDH1A1 (0.39) | GAARIPK1ALDH1A1 | |
| SCHEMBL21384474 | 0.82 | TLR7 (0.37) | ALDH1A1PDE10ASMN1; SMN2LMNADRD1 | |
| SCHEMBL16134181 | 0.78 | NOS3 (0.43) | GAARIPK1NPC1RAB9A | |
| SCHEMBL20428065 | 0.77 | PDE10A (0.32) | ALDH1A1PDE10ASMN1; SMN2LMNANPC1 | |
| SCHEMBL30181916 | 0.77 | — | — | |
| SCHEMBL610170 | 0.77 | — | — | |
| SCHEMBL3878940 | 0.76 | PDE10A (0.43) | ALDH1A1PDE10ASMN1; SMN2LMNADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105324379-B | Benzimidazole derivatives as bromodomain inhibitors | 吉利德科学公司 | 2018-12-04 | — | — | CN | disclosed |
| CN-108884093-A | 6,7,8,9- tetrahydro -5H- pyrido [2,3-d] azepine * dopamine D 3 ligands | 辉瑞公司 | 2018-11-23 | — | — | CN | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| CN-105924386-A | Antiviral Compounds And Uses Thereof | ABBVIE 公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| CN-102448920-B | Antiviral compounds and uses thereof | ABBVIE (US) | 2016-04-06 | — | — | CN | disclosed |
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | ABBVIE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-8748443-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| CN-102448920-A | Antiviral compounds and uses thereof | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| EP-2411352-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111436-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056164-A1 | Antiviral Compounds and Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | GAA 246/4885RIPK1 1518/4885ALDH1A1 2957/4885 |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | GAA 246/4885RIPK1 1518/4885ALDH1A1 2957/4885 |
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | GAA 246/4885RIPK1 1518/4885ALDH1A1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.